Efficacy and safety of combination therapy with eravacycline versus the Best Available Treatment in patients with severe infection in the department of hematology: a multicenter retrospective study

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600120570

Enrollment

Unknown

Registered

2026-03-17

Start date

2026-03-20

Completion date

Unknown

Last updated

2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematological malignancies

Interventions

Eravacycline-based therapy (ERV) group:NA

Best Available Therapy (BAT) group:NA

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years, male or female; 2. Patients from the Department of hematology; 3. Patients from the hematology department with confirmed pathogen detection or highly suspected drug-resistant bacterial infections are recommended to be stratified by infection risk according to the Multinational Association for Supportive Care in Cancer (MASCC) scoring system. A risk score =171 µmol/L; d. Hepatic dysfunction with bilirubin >=33 µmol/L; e. New-onset neurological changes or psychiatric symptoms, such as altered consciousness; f. Diagnosis of sepsis with an increase in SOFA score >=2 points from baseline; g. Requirement for transfer to ICU/HCU for treatment (Definitions for acute respiratory distress refer to the Chinese Guideline for Diagnosis and Non-Invasive Ventilation Treatment of Acute Respiratory Distress Syndrome (ARDS) in Adults (2023); other indicators refer to The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)); 4. Received eravacycline-based combination therapy or BAT regimen (such as combination regimens containing tigecycline, polymyxin, or ceftazidime-avibactam) for >=72 hours.

Exclusion criteria

Exclusion criteria: 1. Infections definitively caused by Pseudomonas aeruginosa as a single pathogen; 2. Non-bacterial infections (such as pure fungal or viral infections); 3. Clinical determination that the outcome is caused by non-bacterial infection.

Design outcomes

Primary

Measure	Time frame
Clinical response rate at test of cure;	—

Secondary

Measure	Time frame
Microbiological eradication rate at the end of treatment;28-day mortality;	—

Countries

China

Contacts

Public ContactHu Yu

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

dr_huyu@126.com+86 27 85726008

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026